Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Valuation

$0000 

Revenue

$0000 

About Dura Pharmaceuticals

Specialty pharmaceutical company focused on respiratory drugs. Acquired by Elan Corporation

Dura Pharmaceuticals Headquarter Location

7475 Lusk Boulevard

San Diego, California, 92121,

United States

858-457-2553

Latest Dura Pharmaceuticals News

Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team

Apr 15, 2015

Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team      April 15, 2015 09:00 ET | Source: Adamis Pharmaceuticals Corporation SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP ) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for the treatment of allergic reactions (Type I) including anaphylaxis. Gus Fernandez, Pharm.D., MBA, has joined Adamis as Vice President of Commercial Operations. In this role, he will work closely with other senior management members to direct all aspects of commercial sales. Most recently, he served as National Business Director for inVentiv Health Commercial Services where he formed, recruited and retained sales teams. Prior to inVentiv, he was VP of Commercial Development and Operations for Avanir Pharmaceuticals where he was responsible for new product planning and commercial operations. Before Avanir, he held several managing roles over a six year period for Dura Pharmaceuticals including Director of Sales Operations. At Dura, he directed a staff of thirteen which supported over 400 sales professionals. He also spent six years as a sales representative for Eli Lilly & Company. Louis J. Fayant, MBA, has joined Adamis as Director of Account Management. For several years, he was Director of Managed Care for Dey L.P. which became a subsidiary of Mylan. There, he oversaw all operations of Dey's US Managed Care Department which impacted over 50% of the company's branded sales, including the EpiPen®. Prior to Dey L.P., he served as Director of Pharmacy Benefit Management for Dura Pharmaceuticals for four years. Before Dura, he spent ten years with Forest Laboratories as a Division Sales Manager and Regional Managed Care Executive growing its formulary access with commercial payers. In addition to his extensive work with EpiPen®, he has also spent over 20 years working in the Asthma/COPD spaces in various capacities. David J. DeLay has also joined Adamis as Senior National Accounts Manager – Alternative Markets. Most recently, he was Director of National Accounts for Halozyme Therapeutics. Prior to Halozyme, he served as Director of National Accounts for Verus Pharmaceuticals where he established TwinJect® stocking in wholesale and retail facilities while securing reimbursement with payers nationwide. For more than a decade, he also served in various account management leadership roles for Vertex Pharmaceuticals, Biovail Pharmaceuticals and Forest Pharmaceuticals. Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "We have strengthened our commercial sales team by adding these talented individuals who will continue to prepare our company for our first commercial product launch. Louis Fayant and David DeLay have worked closely with other products within the anaphylaxis treatment space and bring a wealth of knowledge for growing sales in the managed accounts markets. Gus Fernandez has managed sales operations for highly successful pharmaceutical companies and has invaluable experience with pre-launch planning and on-market commercialization. Their collective expertise and abilities to build and lead top-performing commercial teams will be a great asset to Adamis as we continue towards commercialization of our products. " About Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, APC-2000 for the treatment of bronchospasms, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer. Adamis ContactMark FlatherDirector, Investor Relations &Corporate CommunicationsAdamis Pharmaceuticals Corporation(858) 412-7951Mark GundyExternal Investor Relations972-240-1873 Related Articles

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Dura Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dura Pharmaceuticals is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Dura Pharmaceuticals Patents

Dura Pharmaceuticals has filed 4 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/8/2017

5/18/2021

Cardiac anatomy, Cardiac surgery, Valvular heart disease, Cardiology, Cardiac arrhythmia

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/8/2017

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/18/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac anatomy, Cardiac surgery, Valvular heart disease, Cardiology, Cardiac arrhythmia

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.